Partial characterization of Loxosceles anomala (Mello-Leitão, 1917) venom: A brown spider of potential medical concern.


Journal

Toxicon : official journal of the International Society on Toxinology
ISSN: 1879-3150
Titre abrégé: Toxicon
Pays: England
ID NLM: 1307333

Informations de publication

Date de publication:
01 Jun 2023
Historique:
received: 02 12 2022
revised: 16 03 2023
accepted: 31 03 2023
medline: 8 5 2023
pubmed: 4 4 2023
entrez: 3 4 2023
Statut: ppublish

Résumé

The spider's genus Loxosceles (also known as "brown spiders") is one of the few ones of medical importance in Brazil, being Loxosceles anomala a species of common occurrence in the Southeast region. This species is usually smaller in size than the other members of the Loxosceles group. A single human accident involving L. anomala was reported to date and the clinical picture shared similar characteristics with accidents caused by other Loxosceles species. Despite the potential relevance of L. anomalafor loxocelism in Minas Gerais state, its venom activity has never been characterized. In this work, we provide a preliminary characterization of L. anomala venom, considering its most relevant enzymatic activities and its venom immunorecognition by current therapeutic antivenoms. The results showed that L. anomala venom is immunorecognised by therapeutic antivenoms and by anti-phospholipase D antibodies. Its venom also shows enzymatic activities (sphingomyelinase activity, fibrinogenolytic) described for other Loxosceles venoms. This work contributes to a better knowledge on the venom content and activities of synanthropic Loxosceles species that have the potential of causing relevant human accidents.

Identifiants

pubmed: 37011787
pii: S0041-0101(23)00093-4
doi: 10.1016/j.toxicon.2023.107107
pii:
doi:

Substances chimiques

Antivenins 0
Spider Venoms 0
Phosphoric Diester Hydrolases EC 3.1.4.-

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

107107

Informations de copyright

Copyright © 2023 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Pamella Peres-Damásio (P)

Molecular Toxinology Lab, Research and Development Department, Ezequiel Dias Foundation - FUNED, Belo Horizonte, MG, Brazil.

Rafaela Silva-Magalhães (R)

Molecular Toxinology Lab, Research and Development Department, Ezequiel Dias Foundation - FUNED, Belo Horizonte, MG, Brazil.

Ana Luiza Silva-Araújo (AL)

Molecular Toxinology Lab, Research and Development Department, Ezequiel Dias Foundation - FUNED, Belo Horizonte, MG, Brazil.

Elaine Henriques Teixeira Pereira (EHT)

Molecular Toxinology Lab, Research and Development Department, Ezequiel Dias Foundation - FUNED, Belo Horizonte, MG, Brazil.

Adriano Lima Silveira (AL)

Biótica Estudos Ambientais, João Pinheiro, MG, Brazil.

Luana Silveira da Rocha Nowicki Varella (LSDRN)

Arachnid Proteomics Lab, Research and Development Department, Ezequiel Dias Foundation - FUNED, Belo Horizonte, MG, Brazil.

Márcia Helena Borges (MH)

Arachnid Proteomics Lab, Research and Development Department, Ezequiel Dias Foundation - FUNED, Belo Horizonte, MG, Brazil.

Carlos Chavez-Olórtegui (C)

Biochemistry and Immunology Department, Biological Sciences Institute, Federal University of Minas Gerais - UFMG, Belo Horizonte, MG, Brazil.

Ana Luiza Bittencourt Paiva (ALB)

Molecular Toxinology Lab, Research and Development Department, Ezequiel Dias Foundation - FUNED, Belo Horizonte, MG, Brazil.

Clara Guerra-Duarte (C)

Molecular Toxinology Lab, Research and Development Department, Ezequiel Dias Foundation - FUNED, Belo Horizonte, MG, Brazil. Electronic address: clara.duarte@funed.mg.gov.br.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH